These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 12211042

  • 1. Alphavirus vectors and vaccination.
    Rayner JO, Dryga SA, Kamrud KI.
    Rev Med Virol; 2002; 12(5):279-96. PubMed ID: 12211042
    [Abstract] [Full Text] [Related]

  • 2. Non-viral amplification systems for gene transfer: vectors based on alphaviruses.
    Smerdou C, Liljeström P.
    Curr Opin Mol Ther; 1999 Apr; 1(2):244-51. PubMed ID: 11715947
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic and prophylactic applications of alphavirus vectors.
    Atkins GJ, Fleeton MN, Sheahan BJ.
    Expert Rev Mol Med; 2008 Nov 11; 10():e33. PubMed ID: 19000329
    [Abstract] [Full Text] [Related]

  • 4. Alphavirus DNA and particle replicons for vaccines and gene therapy.
    Polo JM, Gardner JP, Ji Y, Belli BA, Driver DA, Sherrill S, Perri S, Liu MA, Dubensky TW.
    Dev Biol (Basel); 2000 Nov 11; 104():181-5. PubMed ID: 11713818
    [Abstract] [Full Text] [Related]

  • 5. Alphavirus-based vaccines.
    Lundstrom K.
    Curr Opin Mol Ther; 2002 Feb 11; 4(1):28-34. PubMed ID: 11883692
    [Abstract] [Full Text] [Related]

  • 6. Alphavirus vectors for cancer gene therapy (review).
    Yamanaka R.
    Int J Oncol; 2004 Apr 11; 24(4):919-23. PubMed ID: 15010830
    [Abstract] [Full Text] [Related]

  • 7. Alphavirus cDNA-based expression vectors: effects of RNA transcription and nuclear export.
    Boorsma M, Saudan P, Pfruender H, Bailey JE, Schlesinger S, Renner WA, Bachmann MF.
    Biotechnol Bioeng; 2003 Mar 05; 81(5):553-62. PubMed ID: 12514804
    [Abstract] [Full Text] [Related]

  • 8. Alphavirus vectors for cancer therapy.
    Quetglas JI, Ruiz-Guillen M, Aranda A, Casales E, Bezunartea J, Smerdou C.
    Virus Res; 2010 Nov 05; 153(2):179-96. PubMed ID: 20692305
    [Abstract] [Full Text] [Related]

  • 9. Replicon-based vectors of positive strand RNA viruses.
    Khromykh AA.
    Curr Opin Mol Ther; 2000 Oct 05; 2(5):555-69. PubMed ID: 11249758
    [Abstract] [Full Text] [Related]

  • 10. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP, Sun JF, Li N, Sun Y, Wang Y, Qiu HJ.
    Vet Immunol Immunopathol; 2009 Oct 15; 131(3-4):158-66. PubMed ID: 19411115
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of cis-acting elements in the rubella virus subgenomic RNA that play a role in its translation.
    Pappas CL, Tzeng WP, Frey TK.
    Arch Virol; 2006 Feb 15; 151(2):327-46. PubMed ID: 16172842
    [Abstract] [Full Text] [Related]

  • 12. Biology and application of alphaviruses in gene therapy.
    Lundstrom K.
    Gene Ther; 2005 Oct 15; 12 Suppl 1():S92-7. PubMed ID: 16231060
    [Abstract] [Full Text] [Related]

  • 13. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P, Geisbert J, Parker M, Jahrling P, Smith J.
    J Virol; 2001 Dec 15; 75(23):11677-85. PubMed ID: 11689649
    [Abstract] [Full Text] [Related]

  • 14. Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors.
    Vasilakis N, Falvey D, Gangolli SS, Coleman J, Kowalski J, Udem SA, Zamb TJ, Kovacs GR.
    Nat Biotechnol; 2003 Aug 15; 21(8):932-5. PubMed ID: 12845329
    [Abstract] [Full Text] [Related]

  • 15. Japanese encephalitis virus-based replicon RNAs/particles as an expression system for HIV-1 Pr55 Gag that is capable of producing virus-like particles.
    Yun SI, Song BH, Koo Y, Jeon I, Byun SJ, Park JH, Joo YS, Kim SY, Lee YM.
    Virus Res; 2009 Sep 15; 144(1-2):298-305. PubMed ID: 19406175
    [Abstract] [Full Text] [Related]

  • 16. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.
    Greer CE, Zhou F, Legg HS, Tang Z, Perri S, Sloan BA, Megede JZ, Uematsu Y, Vajdy M, Polo JM.
    Vaccine; 2007 Jan 05; 25(3):481-9. PubMed ID: 17052811
    [Abstract] [Full Text] [Related]

  • 17. Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles.
    Goldberg SM, Bartido SM, Gardner JP, Guevara-Patiño JA, Montgomery SC, Perales MA, Maughan MF, Dempsey J, Donovan GP, Olson WC, Houghton AN, Wolchok JD.
    Clin Cancer Res; 2005 Nov 15; 11(22):8114-21. PubMed ID: 16299244
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs.
    Kim DY, Atasheva S, McAuley AJ, Plante JA, Frolova EI, Beasley DW, Frolov I.
    Proc Natl Acad Sci U S A; 2014 Jul 22; 111(29):10708-13. PubMed ID: 25002490
    [Abstract] [Full Text] [Related]

  • 19. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy.
    Riezebos-Brilman A, de Mare A, Bungener L, Huckriede A, Wilschut J, Daemen T.
    J Clin Virol; 2006 Mar 22; 35(3):233-43. PubMed ID: 16448844
    [Abstract] [Full Text] [Related]

  • 20. Alphavirus-based expression vectors: strategies and applications.
    Frolov I, Hoffman TA, Prágai BM, Dryga SA, Huang HV, Schlesinger S, Rice CM.
    Proc Natl Acad Sci U S A; 1996 Oct 15; 93(21):11371-7. PubMed ID: 8876142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.